Serena Williams recently shared that she started taking the GLP-1 drug Zepbound after having her two children. The tennis ...

The tennis star has sparked an online debate about whether or not using GLP-1s for weight loss is taking the easy way out.

Health insurance will grow more expensive in many corners of the market in 2026, and some coverage may shrink.

The mad rush for safe and effective obesity drugs has winners—including Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy—and ...

Celebrities have access to doctors that most others don’t,” says Jameela Jamil, who flagged the risks of GLP-1s like those ...

Burke Wealth Management, an investment management company, released its “Focused Growth Strategy” second-quarter 2025 ...

Jameela Jamil is clarifying her previous statement regarding Serena Williams and GLP-1s. Here's what she said.

About 12% of all U.S. adults have already tried using GLP-1 agonist drugs to control their weight, according to a survey ...

Millions of Americans who have dropped pounds and boosted their health using popular obesity drugs like Wegovy are facing a new dilemma: What happens if they stop taking them? Many worry that they’ll ...

It’s a grand slam partnership for telehealth provider Ro. World renowned tennis star Serena Willams is partnering with the ...

Large U.S. companies expect their health care costs to rise a median of 9% in 2026, according to a survey by the Business Group on Health. That is up from an expected 8% jump in 2025 and the steepest ...